

Eureka Globalstars Project partners Search Form

Contact Person Details	
Name: Camillo Del Cistia	
Position: CTO	
Phone: 55 16 99378 0019	Email: camillo@kimerabiotecnologia.com

Organization Details:							
Name: Kimera Biotech							
Country: Brazil	Website: https://www.kimerabiotech.com/						
Type of	[x] SME	[] Large Company	[] University				
Organization: [] Research I		nst. [] Administration	[] Other (specify):				
Number of	[x]<10	[] 11-50	[] 51-100				
Employees:	[] 101-250	[] > 250					

Describe the activities, products, services, and expertise of your organization:

 Kimera Biotechnology is a startup that emerged in 2014 based on experience in the area of Molecular Biology and Genetics, Cloning and Recombinant DNA Technology, which developed a stable molecule of the hormone Chorionic Gonadotropin, produced in mammalian cells, for use in synchronization protocols of heat and FTAI (Fixed Time Artificial Insemination) of Cattle, Pigs and Sheep, aiming to improve the production system of this hormone which, to this day, is extracted from animals (PMSG) and is the main hormone used for this technique, being also the higher cost.

The information provided here will be used to look for potential partners. All the information provided is public and will be displayed in the matchmaking platform or send to potential partners.

Complete this template and send it back to your national contact point:

- Lieve Apers VLAIO (Belgium, Flanders) lieve.apers@vlaio.be
- Rodrigo Moraes FINEP (Brasil) internacional@finep.gov.br
- Klara Musilova MEYS (Czech Republic) Klara.musilova@msmt.cz
- Rita Silva ANI (Portugal) rita.silva@ani.pt
- Javier Romero CDTI (Spain) josejavier.romero@cdti.es
- Arnold Meijer RVO (The Netherlands) Arnold.meijer@rvo.nl
- Umut Ege Tübitak (Türkiye) eureka@tubitak.gov.tr



Project Details					
Project Title	Development of Biosimilar Hormones to aid in Human Reproduction				
Acronym	DBHHR				
Tech area	Biotech, Human Health, Medicine, Pharmacy				
Keywords	Human Reproduction, Pregnancy, Medicines, Pharmacology,				
	Hormones				

Describe your Project:

We are currently including the development of the hormone Alfafollitropin and hCG in our pipeline. Being a Biosimilar medicine to the reference medicine GONAL-f® and OVIDREL (Merck Serono), it is used to stimulate ovulation in women, supporting assisted reproduction techniques, such as Artificial Insemination, In vitro Fertilization and Embryo Transfer.

Describe the innovative part of your project:

- Through the experience acquired in the development of recombinant hormones for animal reproduction, according to patent (BR2011/000454 e WO2012/083396A1), we decided to also research medicines for human reproduction and we found that there are currently few medicines of this type registered for this purpose, where the medicine GONAL-f® (Merck Serono) It is the main medicine used throughout the world. However, its patent lost protection in 2009 and, to date, two biosimilar medicines have been developed (Bemfola Finox Biotech; Ovaleap Teva Pharma), registered only in Europe.
- Thus, our proposal is to develop a biosimilar medicine to GONAL-f® and OVIDREL, for registration and commercialization initially in Brazil and Europe, where our business model would be carried out through partnerships or licensing and technology transfer.

Describe the market expectations of your project:

- The global assisted reproductive technology market size was valued at USD 25.7 billion in 2022 and is anticipated to expand at a compound annual growth rate (CAGR) of 5.97% during the forecast period.
- Europe IVF Market Size (2023 to 2028) The size of the In-Vitro fertilization (IVF) market in Europe is expected to reach USD 2.31 billion by 2028 from USD 1.13 billion in 2023, growing at a CAGR of 15.4% during the forecast period.
- The reproductive medicine sector is expected to intensify mergers and acquisitions (M&A) activities and grow by an average of 23% per year until 2026 in Brazil, according to an unprecedented study carried out by Redirection International, a company specializing in mergers and acquisitions advisory. The study was carried out using economic and statistical models, based on global and national data from the sector, and points out that the Brazilian market currently moves around R\$ 1.3 billion and will reach the end of 2026 with just over R\$ 3 billion.



The information provided here will be used to look for potential partners. All the information provided is public and will be displayed in the matchmaking platform or send to potential partners.

Complete this template and send it back to your national contact point:

- Lieve Apers VLAIO (Belgium, Flanders) lieve.apers@vlaio.be
- Rodrigo Moraes FINEP (Brasil) internacional@finep.gov.br
- Klara Musilova MEYS (Czech Republic) Klara.musilova@msmt.cz
- Rita Silva ANI (Portugal) rita.silva@ani.pt
- Javier Romero CDTI (Spain) josejavier.romero@cdti.es
- Arnold Meijer RVO (The Netherlands) Arnold.meijer@rvo.nl
- Umut Ege Tübitak (Türkiye) eureka@tubitak.gov.tr

Possible Partner Profile:					
Type of Par	tner Neede	b	[X] SME	[X] Larger Company	
(multiple	choices	are	[X] University	[X] Research Institution	
allowed)			[] Administration	[] Other (specify):	

Describe the expertise of possible partner(s) required for your project:

- Pharmacological Assays (bioavailability, metabolism, toxicology, etc);
- Preclinical Research (pharmacodynamics, pharmacokinetics);
- Clinical Trials;
- Regulatory Affair;
- Pharmacovigilance.

Describe the role of possible partner(s) in your project:

- Scientific and intellectual cooperation in carrying out studies relevant to the development and validation of the proposed object;
- Support in international regulatory affairs and licensing;
- Market, logistics and distribution;
- Professional and personal improvement through international cooperation and mutual work.

Deadline for Partner Search:

The information provided here will be used to look for potential partners. All the information provided is public and will be displayed in the matchmaking platform or send to potential partners.

Complete this template and send it back to your national contact point:



- Lieve Apers VLAIO (Belgium, Flanders) lieve.apers@vlaio.be
- Rodrigo Moraes FINEP (Brasil) internacional@finep.gov.br
- Klara Musilova MEYS (Czech Republic) Klara.musilova@msmt.cz
- Rita Silva ANI (Portugal) rita.silva@ani.pt
- Javier Romero CDTI (Spain) josejavier.romero@cdti.es
- Arnold Meijer RVO (The Netherlands) Arnold.meijer@rvo.nl
- Umut Ege Tübitak (Türkiye) eureka@tubitak.gov.tr